Jan Marini responds to Latisse
This article was originally published in The Rose Sheet
Executive Summary
Marini Lash Eyelash Conditioner "is a safe and cost-effective alternative to the new prescription-based Latisse product by Allergan for consumers seeking dense, lush-looking lashes," according to Jan. 22 release from Jan Marini Skin Research, which provides a head-to-head comparison of the two products. For example, one year of Latisse (12 monthly applications at $120 apiece) costs roughly $1,440, while a year's supply of Marini Lash (two 0.23 oz., $160 tubes) costs $320. JMSR notes that neither Marini Lash nor its companion product, Marini Mascara Performance Mascara, contain bimatoprost - the active drug in Latisse that was used first in an Allergan glaucoma treatment - though an earlier-generation Marini eyelash enhancer did (1"The Rose Sheet" Dec. 15, 2008, p. 7). "With Marini Lash, anyone can have thicker and lusher-appearing lashes without the substantial cost or warning labels that accompany the Latisse prescription product," the company says, adding that it "is also fantastic for eyebrows." Allergan has launched a multi-pronged campaign to raise consumer awareness of Latisse, the only eyelash enhancer with FDA's stamp of approval (2"The Rose Sheet" Jan. 12, 2009, p. 3)
You may also be interested in...
Allergan Creating Awareness For Game-Changing Latisse Eyelash Growth Drug
Allergan is preparing a multi-pronged marketing campaign to make lash-light consumers aware of its recently approved Latisse drug; it remains to be seen how availability of a prescription product with clinically demonstrated effectiveness will impact sales of cosmetic eyelash enhancers
Allergan Eyelash Growth Drug Wins Over FDA Panel, Steps Closer To Approval
FDA's Dermatologic and Ophthalmic Drugs Advisory Committee voted unanimously (9-0) Dec. 5 to recommend approval of Allergan's eyelash growth-stimulating drug, Latisse
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.